Cohort Study of the Clinical Course of Macular Diseases in Japanese Patients
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Initial factors associated with visual prognosis in each macular disease
研究概览
简要总结
Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth.
Patients with such macular diseases are registered and and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who visit Department of Ophthalmology Kyoto University Hospital with macular diseases.
- •Patients who are agreed with the participation of this study.
排除标准
- 未提供
研究组 & 干预措施
Macular diseases
ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
干预措施: ranibizumab, aflibercept, pegaptanib, verteporphin (Drug)
结局指标
主要结局
Initial factors associated with visual prognosis in each macular disease
时间窗: Five years after the registration
次要结局
- The difference in the visual prognosis depending on the treatments in each macular diseases(Five years after the registration)
研究者
Nagahisa Yoshimura
Professor
Kyoto University, Graduate School of Medicine